Bolt Biotherapeutics (NASDAQ:BOLT) Issues Quarterly Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) released its earnings results on Thursday. The company reported ($3.84) earnings per share for the quarter, topping the consensus estimate of ($4.27) by $0.43, FiscalAI reports. The business had revenue of $2.50 million for the quarter.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ BOLT traded up $0.13 during mid-day trading on Friday, hitting $4.18. 8,376 shares of the stock traded hands, compared to its average volume of 26,261. The company has a market cap of $8.02 million, a PE ratio of -0.19 and a beta of 0.94. Bolt Biotherapeutics has a twelve month low of $4.01 and a twelve month high of $9.66. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.57 and a quick ratio of 3.57. The firm has a 50 day simple moving average of $5.44 and a two-hundred day simple moving average of $5.37.

Wall Street Analysts Forecast Growth

BOLT has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, January 21st. Zacks Research downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and an average price target of $34.00.

Hedge Funds Weigh In On Bolt Biotherapeutics

Large investors have recently bought and sold shares of the company. T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $208,000. Renaissance Technologies LLC increased its holdings in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics during the 4th quarter worth $112,000. Susquehanna International Group LLP bought a new position in Bolt Biotherapeutics during the 3rd quarter worth $89,000. Finally, Shay Capital LLC acquired a new position in Bolt Biotherapeutics during the 3rd quarter worth about $85,000. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.